OSL
Oncosil Medical Ltd
$0.7100
▲ +2.16%
Market cap
$26M
Turnover
$87,628
Last price
$0.7100
Day change
+2.16%
Announcements
14
Range, past year
Open 1.660 · Low 0.002 · Now 0.710 · High 2.090
Open OSL in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
OSL momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
33/100
Wyckoff phase
Downtrend8d
Trend stage
Breakdown
1 Day
+2.2%
1 Week
-5.3%
1 Month
-27.6%
1 Year
-57.5%
RSI
31
Avg daily range
7.9%
Oncosil Medical Ltd scores 33 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.80 — highly linear uptrend
Points to watch
- 60d drawdown -48.3%
- High volatility (ATR 7.9%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsOSL announcements
Recent price-sensitive releases.
- 2026-09-09 Australian Manufacturing Facility Achieves ISO 13485 Progress Report
- 2026-09-07 OSL Secures $5.6 million from Major Institutional Investors Placement
- 2026-08-28 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-17 OncoSil Receives FDA Approval for Distal Cholangiocarcinoma Web Cast | Progress Report
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-13 OncoSil Medical Completes Manufacturing Validation
- 2026-07-03 OncoSil Medical Files for FDA Approval
More Health Care stocks
Most traded in the same sector.